First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Short Interest Up 127.1% in April

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totaling 26,983 shares, a growth of 127.1% from the April 15th total of 11,879 shares. Currently, 3.0% of the company’s shares are short sold. Based on an average daily trading volume, of 10,674 shares, the short-interest ratio is presently 2.5 days.

First Trust Nasdaq Pharmaceuticals ETF Stock Performance

NASDAQ FTXH opened at $33.87 on Friday. The stock’s fifty day moving average is $34.01 and its two-hundred day moving average is $33.42. The firm has a market capitalization of $30.48 million, a P/E ratio of 14.51 and a beta of 0.47. First Trust Nasdaq Pharmaceuticals ETF has a fifty-two week low of $24.86 and a fifty-two week high of $35.61.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Thursday, March 26th were paid a dividend of $0.0573 per share. The ex-dividend date of this dividend was Thursday, March 26th. This represents a $0.23 dividend on an annualized basis and a yield of 0.7%.

Hedge Funds Weigh In On First Trust Nasdaq Pharmaceuticals ETF

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. LPL Financial LLC boosted its stake in First Trust Nasdaq Pharmaceuticals ETF by 40.5% during the fourth quarter. LPL Financial LLC now owns 146,105 shares of the company’s stock worth $4,813,000 after buying an additional 42,147 shares during the last quarter. Marshall Investment Management LLC acquired a new position in First Trust Nasdaq Pharmaceuticals ETF during the fourth quarter worth $1,377,000. Goldman Sachs Group Inc. boosted its stake in First Trust Nasdaq Pharmaceuticals ETF by 11.7% during the first quarter. Goldman Sachs Group Inc. now owns 19,472 shares of the company’s stock worth $535,000 after buying an additional 2,047 shares during the last quarter. Envestnet Asset Management Inc. raised its position in First Trust Nasdaq Pharmaceuticals ETF by 2.1% in the third quarter. Envestnet Asset Management Inc. now owns 18,132 shares of the company’s stock valued at $517,000 after purchasing an additional 367 shares during the period. Finally, Ameritas Investment Partners Inc. raised its position in First Trust Nasdaq Pharmaceuticals ETF by 9.7% in the third quarter. Ameritas Investment Partners Inc. now owns 17,232 shares of the company’s stock valued at $491,000 after purchasing an additional 1,521 shares during the period.

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.